GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sichuan Biokin Pharmaceutical Co Ltd (SHSE:688506) » Definitions » Debt-to-Equity

Sichuan Biokin Pharmaceutical Co (SHSE:688506) Debt-to-Equity : 0.15 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sichuan Biokin Pharmaceutical Co Debt-to-Equity?

Sichuan Biokin Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥679 Mil. Sichuan Biokin Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥73 Mil. Sichuan Biokin Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥5,156 Mil. Sichuan Biokin Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2024 was 0.15.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sichuan Biokin Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

SHSE:688506' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.15   Med: 0.74   Max: 4.87
Current: 0.15

During the past 10 years, the highest Debt-to-Equity Ratio of Sichuan Biokin Pharmaceutical Co was 4.87. The lowest was 0.15. And the median was 0.74.

SHSE:688506's Debt-to-Equity is ranked better than
65.21% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs SHSE:688506: 0.15

Sichuan Biokin Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Sichuan Biokin Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Biokin Pharmaceutical Co Debt-to-Equity Chart

Sichuan Biokin Pharmaceutical Co Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.35 0.74 0.54 4.48

Sichuan Biokin Pharmaceutical Co Quarterly Data
Dec11 Dec12 Dec13 Dec14 Jun15 Dec18 Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.86 1.16 4.48 0.15

Competitive Comparison of Sichuan Biokin Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Biokin Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Biokin Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sichuan Biokin Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sichuan Biokin Pharmaceutical Co's Debt-to-Equity falls into.



Sichuan Biokin Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sichuan Biokin Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sichuan Biokin Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Biokin Pharmaceutical Co  (SHSE:688506) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Sichuan Biokin Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sichuan Biokin Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Biokin Pharmaceutical Co (SHSE:688506) Business Description

Traded in Other Exchanges
N/A
Address
No. 161, Baili Road, No. 1, Building 1, Cross-strait Science and Technology Industrial Park, Wenjiang District, Sichuan Province, Chengdu, CHN, 611130
Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.

Sichuan Biokin Pharmaceutical Co (SHSE:688506) Headlines

No Headlines